Navigation Links
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
Date:12/16/2008

SOUTH SAN FRANCISCO, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced top-line results showing that the Phase 3 trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, achieved its primary efficacy endpoint of reducing post-surgical pain versus placebo (p=0.03) following total knee arthroplasty (TKA, or total knee replacement surgery) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005). Adlea is a long-acting, non-opioid drug candidate in development for the management of acute pain following orthopedic surgery.

The Phase 3 TKA trial, known as ACTIVE-2 (Assessment of highly purified Capsaicin To ImproVE pain management after orthopedic surgery), also showed that Adlea's safety profile of adverse events, wound healing, and wound sensory function were similar to placebo over the study duration.

"These compelling results confirm the analgesic contribution of Adlea during the most critical period following total knee arthroplasty with simultaneous opioid sparing effect, all without adding to the systemic side- effects commonly seen with opioids. These results suggest that Adlea has the potential to facilitate early rehabilitation in the knee replacement population," said William Houghton, M.D., Anesiva's senior vice president and chief medical officer.

"The ACTIVE-2 data convincingly validate the value of the Adlea asset and will support our plans to partner or license this product candidate," said Michael L. Kranda, Anesiva's president and chief executive officer.

"Over the past several months, we have revised the company's business model to significantly reduce our burn rate, and will ac
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 ... ISO 13485:2003 certified, GAMP® 5 compliant imaging core ... an international Phase II clinical trial to assess ... , Throughout this trial, Intrinsic Imaging will provide ... limited to, protocol and charter development, site qualification, ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... spintronics, an electronic which is not only based ... their spin and the spin-related magnetism. Spin-charge converters ... and vice versa. Recently, the research group of ... at Johannes Gutenberg University Mainz in collaboration with ... for the first time realised a new, efficient ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 24th Annual Roth ... takes place on Tuesday, March 13 at 2:00 p.m. Pacific ... webcast and may be accessed on the Company,s website at ...
... ATLANTA, March 7, 2012 Harriet L. Robinson, Ph.D., ... a biotech company specializing in the development of HIV/AIDS ... scientists may be one step closer to a vaccine ... study results were unveiled by Dr. Robinson during a ...
... BETHESDA, Md., March 7, 2012   Spherix Incorporated ... innovator in biotechnology for therapy in diabetes, metabolic ... regulatory consulting services to food, supplement, biotechnology and ... its drug candidates, SPX-106T, arrested development and reduced ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 2SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 3SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 4
(Date:8/29/2014)... City, MO. - In a cell,s nucleus, chromosomal ... as histones, an amalgam biologists call chromatin. Until ... a nuclear "sidekick," the mere packing material around ... however, biologists have developed a greater appreciation for ... 2012, investigators from multiple research institutions studying the ...
(Date:8/28/2014)... free mobile app called TX Invasives is now available ... University of Texas at Austin for identifying harmful non-native ... Invasive species in the United States cause about $137 ... destroy agricultural crops, clog waterways, kill native plants and ... Invasives app for reporting where invasive species occur, we,re ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Mobile app makes ID of harmful plants, insects in Texas a snap 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Researchers at the David Geffen School of Medicine at ... proteins known as sodium glucose co-transporters (SGLTs), which pump ... the treatment of chronic diarrhea via oral rehydration therapy, ... The solution of the SGLT structure will accelerate development ...
... have provided vital information to relief workers in Myanmar ... devastating Cyclone Nargis that hit the country on 2 ... the UN Office for the Coordination of Humanitarian Affairs ... Disasters, referred to as ,the Charter, for support by ...
... Want to slow the signs of aging and live longer? ... could be a promising strategy. Calorie restriction has ... and mice. While scientists do not know how calorie restriction ... that it slows aging by decreasing a thyroid hormone, triiodothyronine ...
Cached Biology News:UCLA researchers clarify function of glucose transport molecule 2Extended cyclone relief efforts aided from space 2Extended cyclone relief efforts aided from space 3Looking for the Founatain of Youth? Cut your calories, research suggests 2
RECK (F-20)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... White lyophilized solid. PROTECT FROM ... reversible inhibitor of γ-secretase. Equipotently inhibits the ... = 2.6 μM) and Aβ x-42 ... in HEK293 cells stably transfected with the ...
Biology Products: